For Pre-Launch & Biotech
See what prescribers do today, not just what they say. Before you have a script of your own, we reconstruct from claims how your indication is treated now: who routes to what, after what failed, how long each step holds, and how large the undertreated segment is that nobody is reaching. You come away with a forecast, a sequencing map, and a site list you can defend to a board, an acquirer, or a field team.
One example, from our published research
63 pts
gap in third-line choice between two pathways, same physicians.
Patients coming off photopheresis went to one agent 81.5% of the time. Patients coming off a calcineurin inhibitor went to the other 87% of the time. The prescriber didn’t change. The prior therapy did.
cGVHD Therapy SequencingIn practice
The same physician routes differently depending on what the patient failed before. Segmentation by specialty puts two opposite behaviors in one tier, and a message written for one pathway doesn’t land on the other.
Whether the switch decision lands four months after diagnosis or fourteen changes what your launch has to be ready for on day one, and how long the first wave of eligible patients takes to accumulate. Interviews don’t give you that number. Claims do.
Coverage on a comparable launch is taken from the policy, not from what the payer enforced or what pulled through. The forecast is built on the written version.
Our answer
The answer is never just the headline. Every finding comes with the mechanism behind it, how it has moved over recent quarters, the confounders we tested and ruled out, and an explicit account of what the data cannot tell you.
01
Diagnosed, treated, and undertreated segments, sized at the cohort level. Counts a board can check.
02
Real lines of therapy: who routes to what, after what failed, how long each step holds.
03
How comparable launches were covered and pulled through, payer by payer.
04
Which will move first at launch, and how reimbursement setting and affiliation shape it. Ranked, and ready for your CRM on day one.
Example analyses
A sample. If it’s in claims, it’s in scope.
The output is not a metric. It is a working understanding of your market — the kind you would otherwise assemble by hand, months after it had already shifted again — and a short, ordered list of where your attention should go first.
What we do
Most analytics, human or AI, spend their attention on the question you bring. One question, one answer. The finding that changes a quarter usually sits between hundreds of cross-tabs no one thought to triangulate.
Bring a question.
Your consultant in a pocket. One brand or access question. The defensible answer in five business days, with the mechanism and the accounts behind it.
Watches what you aren't.
Every brand team tracks a set of numbers. Sonar goes after what sits between them.
What you receive
Researcher or Sonar, every project ends with the same five things.
An online report. The full finding and every cut behind it.
An assistant on the report that answers follow-up questions on your own time.
The entities behind the finding. HCPs, accounts, specialty pharmacies, infusion centers, payers — as applicable to the finding — each with a behavioral profile, exportable to your CRM. The outsized drivers, not a spreadsheet no one reads.
A live readout with your account strategy partner — the Flyway analyst who conducted the run and audited the results — and the same partner for follow-ups.
A deck you can forward: the finding, the mechanism, and any accounts behind it, ready for a leadership meeting.
Tell us the change. We'll tell you how we'd go about it, and whether the data can support it.